Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia

被引:4
|
作者
Maiguma, T. [1 ]
Hayashi, Y. [2 ]
Ueshima, S. [2 ]
Kaji, H. [1 ]
Egawa, T. [1 ]
Chayama, K. [4 ]
Morishima, T. [4 ]
Kitamura, Y. [3 ]
Sendo, T. [2 ]
Gomita, Y. [1 ]
Teshima, D. [1 ]
机构
[1] Shujitsu Univ, Dept Clin Pharm, Sch Pharm, Okayama 7038516, Japan
[2] Okayama Univ Hosp, Dept Hosp Pharm, Okayama, Japan
[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Clin Pharmaceut Sci, Okayama, Japan
[4] Okayama Univ Hosp, Dept Pediat, Okayama, Japan
关键词
high-dose methotrexate chemotherapy; pediatric acute lymphoblastic leukemia; oral mucositis; human epidermal keratinocytes; cell viability; pharmacokinetic parameters;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Oral mucositis is a major toxicity in the high-dose methotrexate (HD-MTX) treatment for children with acute lymphoblastic leukemia (ALL). The first aim Of this Study was to evaluate the relationship between the MTX serum concentration and Occurrence of oral mucositis in pediatric ALL patients. The second aim was to clarify the relationship between MTX exposure and epidermal keratinocyte cell injury using an in vitro study. Methods: 49 patients were treated according to the Japan Association of Childhood Leukemia Study (JACLS) ALL-HR02 protocol. This protocol involves HD-MTX treatment (3 g/m(2) for 24-h i.v. infusion). The MTX serum concentrations were measured by a fluorescence polarization immunoassay. The relationship between oral mucositis and MTX serum concentrations 48 and 72 h after administration was determined. The cell toxicity or MTX for epidermal keratinocytes was analyzed by using a cell viability assay (WST-1 assay). In addition, pharmacokinetic evaluation for clearance, AUC extrapolated from 48 h to infinity (AUC(48h-infinity)) and elimination half-life 01,1210 were done using the 1-compartmental models. Results: Oral mucositis occurred in 24 patients (49.0%), in whom 20 patients (83.3% in oral mucositis group) showed WHO severity Grade 1 or 2. Only 4 patients (16.7% in oral mucositis group) showed Grade 3 severity. 22 patients (44.9%) had oral mucositis in the group With a concentration under 10(-6) M 48 h after MTX administration. There was no significant deference among the cell viabilities in the Concentrations of 10(-6) M, 10(-5) M and 10(-4) M 48 h after the MTX exposure. However, the cell viability obtained 24 h after the MTX exposure was significantly different from the respective cell viability 48, 72 and 96 h after the MTX exposure. In the group with oral mucositis, the clearance decreased significantly (p = 0.042), and the t(1/2 beta) (p = 0.025) and AUC(48h-infinity), (P = 0.025) increased significantly compared with the non-symptom group. Conclusions: It seems that there is no significant relationship between the serum MTX concentration and oral mucositis. This in vitro Study has demonstrated that the cell injury was related to the duration of MTX exposure rather than a high MTX concentration.
引用
收藏
页码:584 / 590
页数:7
相关论文
共 50 条
  • [31] Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China
    Xu, Weiqun
    Tang, Yongmin
    Song, Hua
    Shi, Shuwen
    Yang, Shilong
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2007, 29 (10) : 688 - 693
  • [32] High-Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia: Predictors of Delayed Clearance and the Effect of Increased Hydration Rate on Methotrexate Clearance
    Chen, Aaron R.
    Wang, YunZu M.
    Lin, Mark
    Kuo, Dennis J.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (06)
  • [33] Impact of microRNA polymorphisms on high-dose methotrexate-related hematological toxicities in pediatric acute lymphoblastic leukemia
    Zhan, Min
    Liu, Ting
    Zhang, Zhou
    Wang, Guoqiang
    Cao, Zhongqiang
    Li, Xuejuan
    Zeng, Hongwu
    Mai, Huirong
    Chen, Zebin
    FRONTIERS IN PEDIATRICS, 2023, 11
  • [34] Comparison of Capizzi and High-dose Methotrexate Approaches in the Treatment of Pediatric B-cell Acute Lymphoblastic Leukemia
    Gungoren, Ezgi Yalcin
    Koc, Basak
    Zulfikar, Bulent
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2025, 47 (02) : 67 - 73
  • [35] High-dose methotrexate in pediatric acute lymphoblastic leukemia:: Impact of ABCC2 polymorphisms on plasma concentrations
    Rau, Thomas
    Erney, Birgit
    Goeres, Ralf
    Eschenhagen, Thomas
    Beck, Joern
    Langer, Thorsten
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (05) : 468 - 476
  • [36] GENETIC AND METABOLIC DETERMINANTS OF METHOTREXATE INDUCED MUCOSITIS IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
    den Hoed, M.
    Lopez-Lopez, E.
    te Winkel, M. L.
    Tissing, W.
    de Rooij, J. D. E.
    Gutierrez-Camino, A.
    Garcia-Orad, A.
    den Boer, E.
    Pieters, R.
    Pluijm, S. M. F.
    de Jonge, R.
    van den Heuvel-Eibrink, M. M.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S140 - S141
  • [37] Genetic and Metabolic Determinants of Methotrexate Induced Mucositis in Pediatric Acute Lymphoblastic Leukemia
    den Hoed, Marissa
    Lopez-Lopez, E.
    Te Winkel, Mariel L.
    Tissing, Wim
    de Rooij, Jasmijn
    Gutierrez-Camino, A.
    Garcia-Orad, A.
    den Boer, E.
    Pieters, Rob
    Pluijm, S. M. F.
    de Jonge, R.
    van den Heuvel-Eibrink, Marry M.
    BLOOD, 2014, 124 (21)
  • [38] Population Pharmacokinetic Study and Individual Dose Adjustments of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia or Osteosarcoma
    Hui, Ka Ho
    Chu, Ho Man
    Fong, Pui Shan
    Cheng, Wai Tsoi Frankie
    Lam, Tai Ning
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (04): : 566 - 577
  • [39] Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia
    JE Rubnitz
    MV Relling
    PL Harrison
    JT Sandlund
    RC Ribeiro
    GK Rivera
    SJ Thompson
    WE Evans
    C-H Pui
    Leukemia, 1998, 12 : 1176 - 1181
  • [40] High-dose methotrexate in acute lymphoblastic leukemia: Where is the evidence for its continued use?
    Mantadakis, E
    Cole, PD
    Kamen, BA
    PHARMACOTHERAPY, 2005, 25 (05): : 748 - 755